Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 08, 2017 -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the 29th Annual ROTH Conference. Chief Executive Officer Mary Szela is scheduled to present on Tuesday, March 14, 2017 at 2:00 p.m. PDT (5:00 p.m. EDT).
The presentation will be webcast live and may be accessed for up to 90 days following the conference by visiting the “Investors” section of Novelion’s website, www.novelion.com.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT: Amanda Murphy, Director, Investor Relations & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
